Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. Our lead therapeutic drug candidate, TMP-301, is a potent, orally available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) that is being investigated for the treatment of Substance Use Disorders, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD). Additional discovery is also underway on the potential of TMP-301 to treat other addictive disorders, such as Methamphetamine Use Disorder (MUD) and Polysubstance Use Disorder (PUD).
| Website | https://www.temperobio.com |
| Employees | 2 (1 on RocketReach) |
| Founded | 2020 |
| Address | 1111 Broadway Suite 1300, Oakland, California 94607, US |
| Phone | +1 510-227-2102 |
| Industry | Biotechnology Research |
| Keywords | Substance Use Disorder Treatment, Biopharmaceutical, Addiction Treatment, Opioid Addiction Treatment, Clinical Stage, Clinical Trials, Medication Assisted Treatment, Drug Development, Behavioral Health, Therapeutics, Pharmaceutical Research, Novel Therapies, Relapse Prevention, Mental Health, Drug Discovery, Co Occurring Disorders, Biotechnology, Psychiatric Disorders, Treatment Resistant Depression, Patient Care |
Looking for a particular Tempero Bio employee's phone or email?
Tempero Bio Questions
Paul Johnson is the CEO of Tempero Bio.
1 people are employed at Tempero Bio.
Tempero Bio is based in Oakland, California.
Top Tempero Bio Employees
-
Paul Johnson
Chief Executive Officer at Tempero Bio
Moorestown, NJ, US23
Related Companies
